Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

The specific B-cell depleting anti-CD20 monoclonal antibody rituximab (RTX) is effective in terms of the treatment of various immune-mediated glomerulopathies. The administration of RTX has been shown to be reliable and highly effective particularly in patients with ANCA-associated vasculitis, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartinger, Jan Miroslav, Kratky, Vojtech, Hruskova, Zdenka, Slanar, Ondrej, Tesar, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676507/
https://www.ncbi.nlm.nih.gov/pubmed/36420256
http://dx.doi.org/10.3389/fimmu.2022.1024068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676507/
https://www.ncbi.nlm.nih.gov/pubmed/36420256
http://dx.doi.org/10.3389/fimmu.2022.1024068

Ejemplares similares